BioCentury
ARTICLE | Clinical News

QPI-1007: Phase II/III started

November 9, 2015 8:00 AM UTC

SBI Biotech’s Quark Pharmaceuticals Inc. subsidiary began a double-blind, sham-controlled, international Phase II/III trial to evaluate 1.5 and 3 mg QPI-1007 per eye given as a single intravitreal in...